• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿立哌唑每月 1 次给药预防双相障碍患者再住院的效果:一项多中心、1 年回顾性镜像研究。

Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: A multicenter 1-year retrospective mirror image study.

机构信息

Yuge Neuropsychiatric Hospital, Kumamoto, Japan.

Yatsushiro Kosei Hospital, Kumamoto, Japan.

出版信息

Neuropsychopharmacol Rep. 2023 Sep;43(3):425-433. doi: 10.1002/npr2.12371. Epub 2023 Aug 10.

DOI:10.1002/npr2.12371
PMID:37560818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10496053/
Abstract

AIM

We conducted a 1-year retrospective mirror-image study to investigate the effect of aripiprazole once monthly (AOM) on rehospitalization for bipolar disorder.

METHODS

Participants were recruited from psychiatric emergency and acute care hospitals in western Japan. We included 39 participants with bipolar disorder who had been administered AOM for at least 1 year with no missing medical records during the observational period. The primary outcomes were rehospitalization rate, number of rehospitalizations, total hospitalization days, and time to rehospitalization in the context of overall psychiatric readmissions. The significance level was set at p < 0.05.

RESULTS

AOM significantly reduced the rehospitalization rate from 23/39 (59%) to 7/39 (18%) (p = 0.001). The number of rehospitalizations decreased significantly from a mean of 0.85 per person-year to 0.41 per person-year (p = 0.048). The total hospitalization days significantly decreased from a mean of 34.9 days to 14.4 days (p = 0.008). AOM significantly prolonged the time to rehospitalization (p < 0.001).

CONCLUSION

This study found that AOM reduces overall psychiatric rehospitalization for bipolar disorder based on data from 1 year before and after AOM administration in the real-world setting. Future studies should examine the robustness and persistence of the rehospitalization preventive effect of AOM with larger sample sizes and longer observation periods beyond 1 year.

摘要

目的

我们进行了为期 1 年的回顾性镜像研究,以调查阿立哌唑每月 1 次给药(AOM)对双相情感障碍再住院的影响。

方法

参与者来自日本西部的精神科急诊和急性护理医院。我们纳入了 39 名接受 AOM 治疗至少 1 年且在观察期间无缺失病历的双相情感障碍患者。主要结局是在全 Psychiatry 再入院背景下的再住院率、再住院次数、总住院天数和再住院时间。显著性水平设为 p < 0.05。

结果

AOM 显著降低了再住院率,从 23/39(59%)降至 7/39(18%)(p = 0.001)。再住院次数从人均 0.85 次/人年显著减少至 0.41 次/人年(p = 0.048)。总住院天数从人均 34.9 天显著减少至 14.4 天(p = 0.008)。AOM 显著延长了再住院时间(p < 0.001)。

结论

这项研究发现,基于 AOM 给药前后 1 年的真实世界数据,AOM 可降低双相情感障碍的总体 Psychiatry 再住院率。未来的研究应使用更大的样本量和超过 1 年的更长观察期,进一步检验 AOM 预防再住院效果的稳健性和持久性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c651/10496053/6eabebc1bb4e/NPR2-43-425-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c651/10496053/2b05990636ff/NPR2-43-425-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c651/10496053/54b9259a6f4c/NPR2-43-425-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c651/10496053/6eabebc1bb4e/NPR2-43-425-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c651/10496053/2b05990636ff/NPR2-43-425-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c651/10496053/54b9259a6f4c/NPR2-43-425-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c651/10496053/6eabebc1bb4e/NPR2-43-425-g003.jpg

相似文献

1
Preventive effect of aripiprazole once monthly on rehospitalization for bipolar disorder: A multicenter 1-year retrospective mirror image study.阿立哌唑每月 1 次给药预防双相障碍患者再住院的效果:一项多中心、1 年回顾性镜像研究。
Neuropsychopharmacol Rep. 2023 Sep;43(3):425-433. doi: 10.1002/npr2.12371. Epub 2023 Aug 10.
2
Preventive effect of aripiprazole once-monthly on relapse into mood episodes in bipolar disorder: A multicenter, one-year, retrospective, mirror image study.阿立哌唑一月一次给药预防双相情感障碍发作后复发的效果:一项多中心、为期一年、回顾性、镜像研究。
J Affect Disord. 2024 Apr 15;351:381-386. doi: 10.1016/j.jad.2024.01.257. Epub 2024 Jan 30.
3
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.精神分裂症或双相情感障碍患者使用阿立哌唑一月一次 400mg(AOM 400)与口服抗精神病药物相比的药物依从性和停药情况:一项使用美国索赔数据的真实世界研究。
Adv Ther. 2018 Oct;35(10):1612-1625. doi: 10.1007/s12325-018-0785-y. Epub 2018 Sep 11.
4
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.阿立哌唑一月注射一次作为双相 I 障碍维持治疗的症状和功能。
J Affect Disord. 2018 Feb;227:649-656. doi: 10.1016/j.jad.2017.10.035. Epub 2017 Oct 24.
5
Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study.阿立哌唑每月一次给药起始后的精神科医疗资源利用情况:一项回顾性真实世界研究。
Curr Med Res Opin. 2023 Feb;39(2):299-306. doi: 10.1080/03007995.2022.2148461. Epub 2022 Dec 17.
6
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.一项评估阿立哌唑 2 个月长效注射剂用于精神分裂症或双相 I 型障碍成人的安全性、耐受性和药代动力学的随机、开放标签、多剂量、平行臂、关键性研究。
CNS Drugs. 2023 Apr;37(4):337-350. doi: 10.1007/s40263-023-00996-8. Epub 2023 Mar 24.
7
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data.奥氮平起始治疗对精神分裂症患者医疗资源利用和医疗成本的影响:来自美国理赔数据的真实世界证据。
J Med Econ. 2023 Jan-Dec;26(1):316-325. doi: 10.1080/13696998.2023.2178770.
8
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.阿立哌唑作为双相 I 型障碍维持治疗的安全性和耐受性:一项双盲、安慰剂对照、随机撤药研究。
J Affect Disord. 2018 Dec 1;241:425-432. doi: 10.1016/j.jad.2018.06.043. Epub 2018 Jul 6.
9
Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.从口服抗精神病药物转换为每月一次阿立哌唑治疗的患者的住院率:最终疗效分析。
J Med Econ. 2015 Feb;18(2):145-54. doi: 10.3111/13696998.2014.979936. Epub 2014 Nov 10.
10
Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan.在日本真实临床环境中,精神分裂症患者使用长效注射和口服阿立哌唑的治疗持续性。
Adv Ther. 2020 Jul;37(7):3324-3336. doi: 10.1007/s12325-020-01396-w. Epub 2020 Jun 4.

本文引用的文献

1
Predictors of psychiatric hospitalization among outpatients with bipolar disorder in the real-world clinical setting.现实临床环境中双相情感障碍门诊患者精神科住院治疗的预测因素。
Front Psychiatry. 2023 Mar 16;14:1078045. doi: 10.3389/fpsyt.2023.1078045. eCollection 2023.
2
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies.长效注射用抗精神病药物治疗双相情感障碍:来自镜像研究的证据。
Ther Adv Psychopharmacol. 2023 Mar 25;13:20451253231163682. doi: 10.1177/20451253231163682. eCollection 2023.
3
Effect of long-acting injectable antipsychotics on 1-year hospitalization in bipolar disorder: a mirror-image study.
长效注射抗精神病药对双相情感障碍患者 1 年住院的影响:镜像研究。
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1579-1586. doi: 10.1007/s00406-022-01522-5. Epub 2022 Nov 27.
4
Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: A retrospective mirror-image analysis from the Northern Milan Area Cohort (NOMIAC) study.长效注射抗精神病药对双相情感障碍患者急诊就诊和住院的影响:来自米兰北部地区队列(NOMIAC)研究的回顾性镜像分析。
J Affect Disord. 2022 Dec 1;318:88-93. doi: 10.1016/j.jad.2022.08.096. Epub 2022 Sep 2.
5
Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.全球、区域和国家 204 个地区 1990-2019 年 12 种精神障碍疾病的负担:基于 2019 年全球疾病负担研究的系统分析。
Lancet Psychiatry. 2022 Feb;9(2):137-150. doi: 10.1016/S2215-0366(21)00395-3. Epub 2022 Jan 10.
6
Impact of bipolar disorder on health-related quality of life and work productivity: Estimates from the national health and wellness survey in Japan.双相障碍对健康相关生活质量和工作生产力的影响:来自日本全国健康和福利调查的估计。
J Affect Disord. 2021 Dec 1;295:203-214. doi: 10.1016/j.jad.2021.07.104. Epub 2021 Aug 1.
7
Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder - a naturalistic mirror image study.长效注射抗精神病药对双相情感障碍病程和住院的影响——一项自然主义镜像研究。
Nord J Psychiatry. 2022 Jan;76(1):37-43. doi: 10.1080/08039488.2021.1931714. Epub 2021 Jun 14.
8
Real-World Treatment Patterns and Adherence to Oral Medication Among Patients with Bipolar Disorders: A Retrospective, Observational Study Using a Healthcare Claims Database.双相情感障碍患者的真实世界治疗模式及口服药物依从性:一项使用医疗理赔数据库的回顾性观察研究
Neuropsychiatr Dis Treat. 2021 Mar 18;17:821-833. doi: 10.2147/NDT.S299005. eCollection 2021.
9
Neuroprogression as an Illness Trajectory in Bipolar Disorder: A Selective Review of the Current Literature.双相情感障碍中作为疾病轨迹的神经进展:当前文献的选择性综述
Brain Sci. 2021 Feb 23;11(2):276. doi: 10.3390/brainsci11020276.
10
The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.2020 年澳大利亚皇家精神科医学院和新西兰精神科医学院心境障碍临床实践指南。
Aust N Z J Psychiatry. 2021 Jan;55(1):7-117. doi: 10.1177/0004867420979353.